30 October 2023
The Phase 1b stage of the ACCENT trial was designed to test ascending doses of orally-dosed narmafotinib in patients, in combination with the standard-of -care chemotherapy regime of gemcitabine combined with Abraxane. This dose-escalation stage has identified a dose of narmafotinib that provides sufficient circulating drug levels to significantly block the activity of the FAK enzyme. Importantly, this dose has been shown to be safe and well-tolerated across the three cohorts of patients (14 in total) in the trial.
And It does not appear that this "Well-tolerance" has changed during Phase IIA
30 October 2023The Phase 1b stage of the ACCENT trial was...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.8¢ |
Change
-0.008(3.19%) |
Mkt cap ! $110.6M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.5¢ | 22.5¢ | $927.4K | 3.976M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1517946 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 581245 | 12 |
View Market Depth
| Last trade - 10.56am 30/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |